Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05902494 · ClinicalTrials.gov registry record
HER2 and LA/mUC: A Multi-country Chart Review Cohort Study
A clinical trial, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- 389
- Enrollment target
NCT05902494: Completed study, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
NCT05902494 is a clinical trial that has completed, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 389 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05902494 has completed, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- 389 participants
- Enrollment target
Study Summary
This study is being done to learn about urothelial cancers that make HER2 and how that affects treatment choices for participants with urothelial cancer. During this study, the medical and health records of participants will be reviewed to learn more about their health. Participants will have urothelial cancer that has grown in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).
Primary Outcome
The proportion of participants who have a best overall response (BOR) based on complete response (CR) or partial response (PR). The BOR for each participant is the best response (radiographically documented and measurable disease or physician-assessed response) achieved after the start date of the lines of treatment (LOT) prior to the initiation of any subsequent LOT.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 389 participants |
| Start Date | 2023-06-29 |
| Est. Completion | 2025-06-18 |
What the finished NCT05902494 record still lists
NCT05902494 is an observational study that tracks outcomes without assigning an intervention. The registered 389 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05902494 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05902494 about?
NCT05902494 is a clinical study titled "HER2 and LA/mUC: A Multi-country Chart Review Cohort Study". This study is being done to learn about urothelial cancers that make HER2 and how that affects treatment choices for participants with urothelial cancer. During this study, the medical and health records of participants will be reviewed to learn more about their health. Participants will have uroth...
What is the current status of trial NCT05902494?
This trial is currently completed. The enrollment target is 389 participants. The study started on 2023-06-29. Estimated completion is 2025-06-18.
Who is sponsoring clinical trial NCT05902494?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05431088 · 389 participants · Phase 2
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
- NCT00397111 · 390 participants
Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
- NCT05335928 · 390 participants · Phase 3
Abatacept in Immune Checkpoint Inhibitor Myocarditis
- NCT05445960 · 390 participants · NA
Correlation Between Intraoperative Tourniquet Use and Limb pH, Functional Measures and Patient-reported Outcomes After Ankle Fracture Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI